CLINICAL TRIALS PROFILE FOR GELNIQUE 3%

All Clinical Trials for GELNIQUE 3%

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01192568 ↗	Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder	Recruiting	Allergan	Phase 4	2011-05-02	This study will evaluate the safety and efficacy of Oxybutynin Chloride 10% Topical Gel in children 3 to less than 17 years old, who have overactive bladder due to a neurogenic condition. Children will be treated with 0.75 g of gel/day for two weeks. Patients will then return to the clinic for a potential dose titration. At this time their dose may be adjusted up to 1g/day, down to 0.5g/day, or remain the same at 0.75g of gel/day depending on the individual response and tolerability. The total treatment time is 14 weeks and total time on the study is 16 weeks.
NCT01192568 ↗	Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder	Recruiting	Watson Pharmaceuticals	Phase 4	2011-05-02	This study will evaluate the safety and efficacy of Oxybutynin Chloride 10% Topical Gel in children 3 to less than 17 years old, who have overactive bladder due to a neurogenic condition. Children will be treated with 0.75 g of gel/day for two weeks. Patients will then return to the clinic for a potential dose titration. At this time their dose may be adjusted up to 1g/day, down to 0.5g/day, or remain the same at 0.75g of gel/day depending on the individual response and tolerability. The total treatment time is 14 weeks and total time on the study is 16 weeks.
NCT02386072 ↗	A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)	Completed	Astellas Scientific & Medical Affairs, Inc.		2015-01-05	A study to identify factors that are associated with improved effectiveness in pharmacologic therapy of Overactive Bladder, from the patient perspective primarily measured by OAB-Q-SF (Overactive Bladder Questionnaire Short Form)
NCT02633371 ↗	A Pilot Study Exploring the Efficacy and Safety of Topical Oxybutynin 3% Gel for Primary Focal Hyperhidrosis in Adolescents and Young Adults	Completed	Society for Pediatric Dermatology	N/A	2016-02-01	This is a single-center, prospective, open-label, outpatient pilot study evaluating the efficacy and tolerability of oxybutynin gel for axillary hyperhidrosis.

Clinical Trial Conditions for GELNIQUE 3%

Condition Name

Condition Name for GELNIQUE 3%
Intervention	Trials
Hot Flashes	1
Hyperhidrosis	1
Lobular Breast Carcinoma In Situ	1
Neurogenic Bladder	1

Condition MeSH

Condition MeSH for GELNIQUE 3%
Intervention	Trials
Urinary Bladder, Overactive	2
Carcinoma	1
Diabetic Neuropathies	1
Urinary Bladder, Neurogenic	1

Clinical Trial Locations for GELNIQUE 3%

Trials by Country

Trials by Country for GELNIQUE 3%
Location	Trials
United States	58
Canada	4

Trials by US State

Trials by US State for GELNIQUE 3%
Location	Trials
Virginia	3
North Carolina	3
Michigan	3
Colorado	3
Kansas	2

Clinical Trial Progress for GELNIQUE 3%

Clinical Trial Phase

Clinical Trial Phase for GELNIQUE 3%
Clinical Trial Phase	Trials
Phase 4	1
Phase 3	2
N/A	1

Clinical Trial Status

Clinical Trial Status for GELNIQUE 3%
Clinical Trial Phase	Trials
Completed	4
Recruiting	1

Clinical Trial Sponsors for GELNIQUE 3%

Sponsor Name

Sponsor Name for GELNIQUE 3%
Sponsor	Trials
Allergan	1
Watson Pharmaceuticals	1
Astellas Scientific & Medical Affairs, Inc.	1

Sponsor Type

Sponsor Type for GELNIQUE 3%
Sponsor	Trials
Industry	4
Other	4
NIH	2